Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
Vera Therapeutics announced the final efficacy analysis of its Phase 3 ORIGIN 3 trial showing TRUTAKNA (atacicept-vymj) achieved statistical significance in all prespecified endpoints in adults with primary IgA nephropathy at risk of disease progression. The primary endpoint of proteinuria reduction at 36 weeks was met, with additional significant reductions in urine-protein-to-creatinine ratio, Gd-IgA1, and hematuria, plus a safety profile generally comparable to placebo (7% serious adverse events vs 15% on placebo). Results were presented at ASN Kidney Week 2026 and published in the New England Journal of Medicine.
Key figures
- Drug Name
- TRUTAKNA (atacicept-vymj)
- Phase Of Trial
- Phase 3 (ORIGIN 3)
- Sbla submission
- Q4 2026
- Primary endpoint
- statistically significant proteinuria reduction at 36 weeks
- Sae rate placebo
- 15%
- Sae rate trutakna
- 7%
- Full approval expected
- 2027
- Infection rate placebo
- 52.3%
- Infection rate trutakna
- 51.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.